104 related articles for article (PubMed ID: 19919817)
1. No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo.
Kreutzer J; Jeske I; Hofmann B; Blumcke I; Fahlbusch R; Buchfelder M; Buslei R
Clin Neuropathol; 2009; 28(6):430-9. PubMed ID: 19919817
[TBL] [Abstract][Full Text] [Related]
2. A novel somatostatin receptor ligand for human ACTH - and GH -secreting pituitary adenomas.
Regazzo D; Avallone S; MacSweeney CP; Sergeev E; Howe D; Godwood A; Bennett KA; Brown AJH; Barnes M; Occhi G; Barbot M; Faggian D; Tropeano MP; Losa M; Lasio G; Scaroni C; Pecori Giraldi F
Eur J Endocrinol; 2024 Jan; 190(1):K8-K16. PubMed ID: 38123488
[TBL] [Abstract][Full Text] [Related]
3. Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas.
Sekizaki T; Kameda H; Nakamura A; Kuwabara S; Nomoto H; Cho KY; Ishi Y; Motegi H; Miyoshi H; Atsumi T
Pituitary; 2023 Oct; 26(5):597-610. PubMed ID: 37642928
[TBL] [Abstract][Full Text] [Related]
4. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
Perosevic M; Tritos NA
Drug Des Devel Ther; 2023; 17():1303-1312. PubMed ID: 37143705
[TBL] [Abstract][Full Text] [Related]
5.
De Sousa SMC; Shen A; Yates CJ; Clifton-Bligh R; Santoreneos S; King J; Toubia J; Trivellin G; Lania AG; Stratakis CA; Torpy DJ; Scott HS
Front Endocrinol (Lausanne); 2023; 14():1305606. PubMed ID: 38075079
[TBL] [Abstract][Full Text] [Related]
6. Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN.
Valassi E; Castinetti F; Ferriere A; Tsagarakis S; Feelders RA; Netea-Maier RT; Droste M; Strasburger CJ; Maiter D; Kastelan D; Chanson P; Webb SM; Demtröder F; Pirags V; Chabre O; Franz H; Santos A; Reincke M
Endocr Relat Cancer; 2022 Dec; 29(12):681-691. PubMed ID: 36197784
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase C delta mediates Pasireotide effects in an ACTH-secreting pituitary tumor cell line.
Gentilin E; Borges De Souza P; Ambrosio MR; Bondanelli M; Gagliardi I; Zatelli MC
J Endocrinol Invest; 2023 Dec; 46(12):2609-2616. PubMed ID: 37233978
[TBL] [Abstract][Full Text] [Related]
8. A novel human tumoroid 3D model of sustained ACTH-secreting cell cultures to study critically needed therapies for Cushing's disease.
Fuentes-Fayos AC; Luque RM
EBioMedicine; 2021 May; 67():103368. PubMed ID: 33993049
[No Abstract] [Full Text] [Related]
9. Sexual Dimorphism in Cellular and Molecular Features in Human ACTH-Secreting Pituitary Adenomas.
Pecori Giraldi F; Cassarino MF; Sesta A; Terreni M; Lasio G; Losa M
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32183012
[TBL] [Abstract][Full Text] [Related]
10. Osilodrostat for Cushing Disease and Its Role in Pediatrics.
Groselj U; Sikonja J; Battelino T
Horm Res Paediatr; 2023; 96(6):573-580. PubMed ID: 35045421
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons.
Brodbeck J; Balestra ME; Saunders AM; Roses AD; Mahley RW; Huang Y
Proc Natl Acad Sci U S A; 2008 Jan; 105(4):1343-6. PubMed ID: 18212130
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome-proliferator activator receptor-gamma activation decreases attachment of endometrial cells to peritoneal mesothelial cells in an in vitro model of the early endometriotic lesion.
Kavoussi SK; Witz CA; Binkley PA; Nair AS; Lebovic DI
Mol Hum Reprod; 2009 Oct; 15(10):687-92. PubMed ID: 19643817
[TBL] [Abstract][Full Text] [Related]
13. A PPAR-gamma agonist protects from radiation-induced intestinal toxicity.
Mangoni M; Sottili M; Gerini C; Desideri I; Bastida C; Pallotta S; Castiglione F; Bonomo P; Meattini I; Greto D; Cappelli S; Di Brina L; Loi M; Biti G; Livi L
United European Gastroenterol J; 2017 Mar; 5(2):218-226. PubMed ID: 28344789
[TBL] [Abstract][Full Text] [Related]
14. Management of Nelson's Syndrome.
Fountas A; Karavitaki N
Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36363537
[TBL] [Abstract][Full Text] [Related]
15. Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations.
Reincke M; Albani A; Assie G; Bancos I; Brue T; Buchfelder M; Chabre O; Ceccato F; Daniele A; Detomas M; Di Dalmazi G; Elenkova A; Findling J; Grossman AB; Gomez-Sanchez CE; Heaney AP; Honegger J; Karavitaki N; Lacroix A; Laws ER; Losa M; Murakami M; Newell-Price J; Pecori Giraldi F; Pérez-Rivas LG; Pivonello R; Rainey WE; Sbiera S; Schopohl J; Stratakis CA; Theodoropoulou M; van Rossum EFC; Valassi E; Zacharieva S; Rubinstein G; Ritzel K
Eur J Endocrinol; 2021 Mar; 184(3):P1-P16. PubMed ID: 33444221
[TBL] [Abstract][Full Text] [Related]
16. Rapid response of Nelson's syndrome to pasireotide in radiotherapy-naive patient.
He X; Spencer-Segal JL
Clin Diabetes Endocrinol; 2020 Nov; 6(1):22. PubMed ID: 33292741
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory Effects of a Novel PPAR-
Parvin R; Noro E; Saito-Hakoda A; Shimada H; Suzuki S; Shimizu K; Miyachi H; Yokoyama A; Sugawara A
PPAR Res; 2018; 2018():5346272. PubMed ID: 29849538
[TBL] [Abstract][Full Text] [Related]
18. The Treatment of Cushing's Disease.
Pivonello R; De Leo M; Cozzolino A; Colao A
Endocr Rev; 2015 Aug; 36(4):385-486. PubMed ID: 26067718
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of pharmacological therapy in Cushing's disease.
Ferone D; Pivonello C; Vitale G; Zatelli MC; Colao A; Pivonello R
Endocrine; 2014 Jun; 46(2):181-98. PubMed ID: 24272603
[TBL] [Abstract][Full Text] [Related]
20. Cushing's syndrome: all variants, detection, and treatment.
Sharma ST; Nieman LK
Endocrinol Metab Clin North Am; 2011 Jun; 40(2):379-91, viii-ix. PubMed ID: 21565673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
